[ad_1] The pharmaceutical company says its sales could be as much as $3 billion lower this year than initially expected. [ad_2] Source link Source link
Read MoreTag: Merck &
[ad_1] Rival drugmakers are seeking to upend Pfizer Inc.’s dominance of the $7 billion worldwide market for pneumonia vaccines, launching what is shaping up to be one of the industry’s fiercest battles. Merck & Co. has already introduced a new competitor to Pfizer’s Prevnar vaccine franchise, while GSK PLC and Vaxcyte Inc. are among companies […]
Read More